{"id":61995,"date":"2024-11-26T00:04:57","date_gmt":"2024-11-26T00:04:57","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/11\/26\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/"},"modified":"2024-11-26T00:04:57","modified_gmt":"2024-11-26T00:04:57","slug":"olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/","title":{"rendered":"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium"},"content":{"rendered":"<div>\n<p><em>Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024<\/em><\/p>\n<p align=\"left\">SAN FRANCISCO, Nov.  25, 2024  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=56BsBXv_odF17sB4wVEt1-sgJgvYxCrnXKzgHUdsBjTiReBSwa_x1Qa4pQC_Oq9KyZKZ_JvCHmkQfMXyYJT0MkN2mDxmSV9g5SujIDUkIec=\" rel=\"nofollow\" target=\"_blank\" title=\"Olema Pharmaceuticals, Inc.\">Olema Pharmaceuticals, Inc.<\/a> (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b\/2 clinical study of palazestrant (OP-1250) in combination with CDK4\/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.<\/p>\n<p><em>Poster Details<\/em><\/p>\n<ul type=\"disc\">\n<li><strong>Title:<\/strong> A Phase 1b\/2 study of palazestrant (OP-1250) in combination with ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+\/HER2-), advanced or metastatic breast cancer<\/li>\n<li><strong>Poster ID:<\/strong> P2-09-16<\/li>\n<li><strong>Session:<\/strong> Poster Session 2<\/li>\n<li><strong>Date\/Time:<\/strong> Wednesday, December 11, 2024, from 5:30 to 7:00 p.m. CT<\/li>\n<li><strong>Location:<\/strong> Halls 2-3<\/li>\n<\/ul>\n<p>Additional information, including the abstract for this presentation, can be found on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LUcVTHpRjoMYOp3W4_ktT8tqGN9RqfVR4C3j8X-IDNZjY8Sef820V7D3_6atVqckQHqy04_3PBdO5Z83ljm-Og==\" rel=\"nofollow\" target=\"_blank\" title=\"SABCS website\">SABCS website<\/a>. A copy of the poster will be made available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=723Yc14zRq38k4wsDO3zum414M6kuwDVxE5csod-wyzGLwi_8HqomY5X5lkQmCXNpOx8RQtgd2rltsdRVbWZwacqOlxtAeHWTr4h7DVgtJY=\" rel=\"nofollow\" target=\"_blank\" title=\"Publications\">Publications<\/a> page of Olema\u2019s website in alignment with the Symposium\u2019s embargo policy.<\/p>\n<p><strong>Conference Call Information<\/strong><br \/>Olema will hold a conference call to discuss these data with the investment community on Tuesday, December 10, 2024, at 8:00 a.m. ET\/7:00 a.m. CT. Register to join the webcast by visiting the Events page on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ADuoJ7lzgPO2TYbQEcxTfmIT1U1XFTTVJuFVlipO1YUfYmGytikFtGccROyBSvsHtA00Xwt915R3tO3UEQxtcA==\" rel=\"nofollow\" target=\"_blank\" title=\"Investors and Media\">Investors and Media<\/a> section of Olema\u2019s website.<\/p>\n<p><strong>About Palazestrant (OP-1250)<\/strong><br \/>Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In preclinical studies, palazestrant completely blocks ER-driven transcriptional activity in both <em>ESR1<\/em> wild-type and mutant forms of breast cancer cell. In Olema\u2019s ongoing clinical trials for advanced or metastatic ER+\/HER2- breast cancer, palazestrant has demonstrated anti-tumor activity along with attractive pharmacokinetics and exposure, favorable tolerability, and combinability with CDK4\/6 inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+\/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4\/6 inhibitor. It is being evaluated both as a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and in Phase 1\/2 combination studies with CDK4\/6 inhibitors (palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib), and an mTOR inhibitor (everolimus). For more information on OPERA-01, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r2llbX662pFc5YLEm_2f01vHr8nki3O21PHZp0BYdORKY7511hn2befRVtmragFPeOL9DfVY3-dF_UQbIOqAVUhuzTRn_LOVayyaHmAplFY=\" rel=\"nofollow\" target=\"_blank\" title=\"www.opera01study.com\">www.opera01study.com<\/a>.<\/p>\n<p><strong>About Olema Oncology<\/strong><br \/>Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r2llbX662pFc5YLEm_2f040u8jpquqRVLqCarQ1_JaDCv_UDEx_7qxoPD_nL3b5k8n4TIPG_X3nDl8DogAAbOQ==\" rel=\"nofollow\" target=\"_blank\" title=\"www.olema.com\">www.olema.com<\/a>.<\/p>\n<p><strong>Media and IR Contact<\/strong><br \/>Courtney O\u2019Konek<br \/>Vice President, Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hrGrcMPSJpcCGOjMc7GXolGxir3ccblCA9AGUa1ATyw_S2iy_Xd0J26CVAKJrVPkKzbAwtPaRKdcqPQCvicOog==\" rel=\"nofollow\" target=\"_blank\" title=\"media@olema.com\">media@olema.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWFhNTU4MDUtZTU3Ni00ZTQxLWIwOGQtMTc1MWZlODA4NTliLTEyMTUwNjg=\/tiny\/Olema-Pharmaceuticals-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it [&#8230;]\n","protected":false},"author":1,"featured_media":61996,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61995","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium\" \/>\n<meta property=\"og:description\" content=\"Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceu\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-26T00:04:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Olema-Pharmaceuticals-Inc-1-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium\",\"datePublished\":\"2024-11-26T00:04:57+00:00\",\"dateModified\":\"2024-11-26T00:04:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/\"},\"wordCount\":579,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/\",\"name\":\"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-11-26T00:04:57+00:00\",\"dateModified\":\"2024-11-26T00:04:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium","og_description":"Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceu","og_url":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-11-26T00:04:57+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/11\/Olema-Pharmaceuticals-Inc-1-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium","datePublished":"2024-11-26T00:04:57+00:00","dateModified":"2024-11-26T00:04:57+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/"},"wordCount":579,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/","url":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/","name":"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-11-26T00:04:57+00:00","dateModified":"2024-11-26T00:04:57+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/olema-oncology-to-present-new-data-combining-palazestrant-with-ribociclib-at-the-san-antonio-breast-cancer-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=61995"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/61995\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/61996"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=61995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=61995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=61995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}